newsfilter
← Latest News
Business Wire·

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable